Last reviewed · How we verify
NCT01543672: VOLUMES
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
Phase 1, PHASE2 trial testing Stereotactic Body Radiotherapy (SBRT) in Lung Cancer in 62 participants. Completed in 31 October 2017.
31 October 2017
Quick facts
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 22 November 2011 |
| Primary completion | 31 October 2017 |
| Estimated completion | 31 October 2017 |
| Sites | 5 locations across Netherlands, Canada, United States, Germany |
Drugs / interventions tested
- Stereotactic Body Radiotherapy (SBRT) — full drug profile →
- Stereotactic Body Radiotherapy (SBRT) — full drug profile →
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Metastatic Lung Cancer — all drugs for Metastatic Lung Cancer →
Sponsor
The Netherlands Cancer Institute
Who can join
18 and older, any sex, with Lung Cancer or Metastatic Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01543672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic Body Radiotherapy (SBRT)
Trials testing the same drug.
- NCT07075120 — Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer · Phase 1 · not yet recruiting
- NCT07030140 — Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Chola · Phase 2 · not yet recruiting
- NCT06641791 — Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck C · Phase 3 · recruiting
- NCT06218420 — Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Live · Phase 2 · recruiting
- NCT04572451 — Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom · Phase 1 · recruiting
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other The Netherlands Cancer Institute trials
Trials by the same sponsor.
- NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01543672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
- Last refreshed: 27 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01543672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing